INDV

RICHMOND, Va., April 16, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (NASDAQ:INDV) today announced results from a national survey published in the Journal of Correctional Health Care showing that correctional leaders identify staffing and coordination gaps as key barriers to reducing diversion of medications for opioid use disorder (MOUD) and recognized long-acting injectable (LAI) buprenorphine as a strategy to help mitigate diversion and improve treatment in jail and prison settings. The cross-sectional survey included responses from 180 correctional professionals across U.S. jail and prison facilities. Among respondents, a strong majority — 88% of those working in jails and 87% in prisons —

RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. Live webcast link: https://edge.media-server.com/mmc/p/3k7nbxjp Participants may acc

Model estimates SUBLOCADE® may reduce staff time and associated costs compared with other medications for opioid use disorder in jails and prisons RICHMOND, Va., March 31, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (NASDAQ:INDV) today announced findings from a new cost impact model published in The Journal of Current Medical Research and Opinion, estimating that the use of extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, may reduce staff time and associated costs in jails and prisons compared with other medications for opioid use disorder (MOUD). "Correctional facilities face ongoing staffing constraints as the need for MOUD conti

DEFA14A - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)

DEF 14A - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)

SCHEDULE 13G - Indivior Pharmaceuticals, Inc. (0001625297) (Subject)

4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

8-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)

Jails outpace prisons in offering MOUD, but regional disparities and limited treatment access persist across the U.S.Qualitative feedback points to need for greater reentry support, housing, care coordination, and provider training RICHMOND, Va., March 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals Inc. (NASDAQ:INDV) announced results from a cross-sectional survey published in the Journal of Correctional Health Care that reveal critical gaps in the availability of medications for opioid use disorder (MOUD) across U.S. correctional facilities. Funded by Indivior and conducted in partnership with the National Commission on Correctional Health Care (NCCHC), the study surveyed 212 jai

4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convertible senior notes due 2031 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previously announced offering size of $400,000,000 aggregate principal amount of notes. Indivior also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $50,000,000 principal amount of notes. The sale o

8-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)

RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate principal amount of convertible senior notes due 2031 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Indivior also expects to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $60,000,000 principal amount of notes. The notes will be senior, unsecured obligations of Indivior, will accrue interest payable semi-a

4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

Patients adherent to SUBLOCADE® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUDPatients adherent to SUBLOCADE had the lowest inpatient, emergency department, and detoxification utilization across all treatment groups RICHMOND, Va., March 11, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals (NASDAQ:INDV) today announced findings from a new real-world evidence, retrospective observational study published in Frontiers in Public Health showing that adherence to SUBLOCADE® (extended-release buprenorphine), a monthly injectable, is associated with meaningfully lower healthcare utilization and medical costs among commercially insured patient

4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

10-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)

8-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)

Generated Record Quarterly and Full-Year Total SUBLOCADE® Net Revenue of $252 Million and $856 MillionAchieved Quarterly and Full-Year GAAP Net Income of $102 Million and $210 Million; Non-GAAP Quarterly and Full-Year Net Income of $107 Million and $320 MillionDelivered Record Quarterly and Full-Year Adjusted EBITDA of $142 Million and $428 MillionEntered Phase II of the Indivior Action Agenda – Accelerate – on January 1, 2026Authorized New $400 Million Share Repurchase ProgramReaffirmed Full-Year 2026 Financial Guidance Announced on January 8, 2026Conference Call at 8:00 A.M. EST Today RICHMOND, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today

RICHMOND, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will participate in the following upcoming investor conferences: Barclays 28th Annual Global Healthcare Conference – Miami, FLJoe Ciaffoni, Chief Executive Officer, will host 1x1 / group meetings on Tuesday, March 10th. Joe Ciaffoni will also participate in a fireside chat on Tuesday, March 10th at 2:00 p.m. U.S. EST. Interested investors should contact their Barclays representative to schedule a meeting. The fireside chat will be publicly available and can be accessed using the following weblink: Barclays Webcast Link. 2026 Jefferies Biotech on the Beach Summit – Miami,

SCHEDULE 13G - Indivior Pharmaceuticals, Inc. (0001625297) (Subject)